In a report released on January 27, David Grossman from Stifel Nicolaus maintained a Hold rating on Tabula Rasa HealthCare (TRHC – Research Report), with a price target of $6.50. The company’s shares closed last Friday at $6.01.
According to TipRanks, Grossman is a 5-star analyst with an average return of 15.9% and a 66.99% success rate. Grossman covers the Technology sector, focusing on stocks such as International Business Machines, Tabula Rasa HealthCare, and Epam Systems.
In addition to Stifel Nicolaus, Tabula Rasa HealthCare also received a Hold from SVB Securities’s Stephanie Davis in a report issued on January 17. However, on the same day, RBC Capital maintained a Buy rating on Tabula Rasa HealthCare (NASDAQ: TRHC).
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $10.92 and a one-year low of $2.09. Currently, Tabula Rasa HealthCare has an average volume of 102.1K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TRHC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tabula Rasa Healthcare, Inc. engages in the development of pharmaceutical software that optimizes medication regimens. It offers cloud-based applications, such as EireneRx and MedWise Advisor. The company was founded by Calvin H. Knowlton and Orsula V. Knowlton in April 2009 and is headquartered in Moorestown, NJ.
Read More on TRHC:
